newsfilter
← Latest News
PR Newswire·

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg...